It is considered that COVID‐19's pandemic expansion is responsible for the particular
increase in deaths, especially among the population with comorbidities. The health system …

Abstract Scope In 2009, the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) published the first treatment guidance document for Clostridioides …

Clostridioides difficile is often resistant to the actions of antibiotics to treat other bacterial
infections and the resulting C. difficile infection (CDI) is among the leading causes of …

Objectives Clostridioides difficile infection (CDI), its subsequent recurrences (rCDIs), and
severe CDI (sCDI) provide a significant burden for both patients and the healthcare system …

Background Although comorbidities are risk factors for recurrent Clostridioides difficile
infection (rCDI), many clinical trials exclude patients with medical conditions such as …

Early life is a vital period for mammals to be colonized with the microbiome, which
profoundly influences the development of the intestinal immune function. For neonates to …

Objectives Treatment guidelines are key drivers of prescribing practice in the management
of Clostridioides difficile Infection (CDI), but recommendations on best practice can vary. We …

Purpose Patients with cancer are vulnerable to Clostridioides difficile infection (CDI) due to
their disease, treatment and regular hospital contact, yet if CDI-recurrence is more common …

(1) Background: The Charlson comorbidity index (CCI) score has been shown to predict 10-
year all-cause mortality, but its validity is a matter of debate in surgical patients. We wanted …

Clostridioides difficile infection (CDI) may recur in approximately 10–30% of patients, and
the risk of recurrence increases with each successive recurrence, reaching up to 65%. C …